Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...

Johnson & Johnson (JNJ) announced on Friday the achievement of a primary safety endpoint in a Phase 1 trial for a drug ...

Johnson & Johnson has just undergone its most significant transformation in decades. In 2023, the consumer health segment was spun off as Kenvue. Now, the orthopedic division is set to be separated as ...

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...

Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for cataract surgery.

Johnson & Johnson's (JNJ) stock is in focus as the FDA approves a multiple myeloma therapy developed by the company with Halozyme (HALO). Read more here.

Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, making them direct peers in the blue-chip healthcare space. Both companies ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) primarily due to waning demand for its COVID-19 products, a significant ...

Johnson & Johnson JNJ will begin the earnings season for the drug & biotech sector when it reports its fourth-quarter and full-year 2025 results on Jan. 21. The Zacks Consensus Estimate for ...

Johnson & Johnson (JNJ) units will pay $65M to settle a Tracleer antitrust class action over alleged delays to generic competition. Read more here.